New Study Demonstrates Bryostatin Normalizes Autistic Spectrum Behaviors in Mice
- Peer Reviewed Article Published through Nature.com
News provided by
Share this article
Share this article
NEW YORK, Jan. 26, 2021 /PRNewswire/ Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced a new report published by Scientific Reports, an open-access journal publishing peer reviewed research through Nature.com, titled Chronic Bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice. This new study, in collaboration with the Fragile X Foundation and scientists in the United Kingdom, highlights that Bryostatin has potential applicability for autistic spectrum disorders. The results show the potential of Bryostatin to regenerate synapses in other degenerative brain disorders that produce autistic spectrum behaviors. Bryostatin s regenerative potential has been previously demonstrated during the past two decades for pre-clinical models of